Bowel Management Systems Market In Depth Study And Analysis Published, 2023

 Rapid change in lifestyles and unhealthy dietary habits is leading to the rise in intestinal issues such as fecal incontinence and constipation among adults. With advancement in healthcare technology and development of various medical devices, these health issues are being managed with the help of bowel management systems.

Market Research Future (MRFR) has published a report asserting that the global bowel management systems market is marked to expand steadily at a CAGR of 4.1% during the forecast period of 2017-2023 and reach the valuation of 2.188 Bn by the end of 2023 from 1.72 Bn in 2017.
Global rise in geriatric population and dietary imbalance caused due to consumption of unhealthy food are majorly propelling the growth of the global bowel management systems market. However, concerns regarding the discomfort associated with the use of bowel management devices and inclination towards adoption of non-invasive treatments are likely to restrain the growth of the global bowel management systems market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6649

Companies Covered

The leading players operating in the global bowel management systems market are Coloplast (Denmark), Medtronic (Ireland), 3M (the U.S.), B. Braun (Germany), C.R. Bard (the U.S.), Consure Medical (India), Cogentix Medical (the U.S.), Aquaflush Medical Limited (the U.K.), Axonics Modulation Technologies (the U.S.), ConvaTec (the U.K.), Hollister (the U.S.), MBH-International A/S (Denmark), Mederi Therapeutics Inc. (the U.S.), Welland Medical limited (the U.K.), and Wellspect HealthCare (Sweden).

Market Segmental Analysis

For scope of the report, MRFR offers a comprehensive segmental analysis of the global bowel management systems market

By Product

• Irrigation Systems 
• Colostomy Bags
• Nerve Modulation Devices (NMD)
• Other Products and Accessories

By Patient Type

• Adult Patients
• Pediatric Patients

By End User

• Home Care
• Hospitals & Ambulatory Surgery Centers

By Region

• Americas
• Europe
• Asia-Pacific
• Middle East and Africa

Report Overview

The MRFR’s market research report offers an unbiased and comprehensive assessment of key market dynamics in the global bowel management systems market. It includes discussion on current and historical market trends, challenges and growth opportunities backed by factful feedbacks. The primary types of products that are covered in the report are irrigation systems, colostomy bags, nerve modulation devices (NMD) and other products and accessories. The types of patients covered in the report are adult patients and pediatric patients. For opportunity analysis, the major end-users covered in the report are home care and hospitals and ambulatory surgery centers. All the sub-markets included in the report are profiled under four major regions such as Europe, Asia Pacific, Americas and the Middle East and Africa, with respective country-level analysis.

Research Methodology

Market Research Future (MRFR) leverages its comprehensive and iterative research methodology for the deliverance of highly accurate market insights. The primary and secondary research processes are utilized for conducting qualitative and quantitative analysis of current and historical market dynamics, consumer landscape, competitive landscape, market growth opportunities and challenges. Detailed surveys and first-hand interviews are conducted with the key opinion makers across the value chain for the collection of primary data. Secondary research processes are utilized for primary data validation through inputs from SEC filings, white paper references, paid databases, research publications and other credible sources available in public domain. The data triangulation techniques and top-down and bottom-up approaches are utilized to ensure accuracy and objectivity of the research findings.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/bowel-management-systems-market-6649

Lupus Market Expected To Boost During 2020 To 2023

 The Global Lupus Market is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 1.48 billion in 2017 and is projected to grow at a CAGR of 11.2% over the forecast period. Lupus is a systemic autoimmune disease that causes inflammation throughout the body.  In patients with lupus, the immune system attacks healthy cells and tissues of the body which can result in damage to many parts of the body including the skin, joints, kidney, heart, lungs, blood vessels, and brain. The factors such as the rising prevalence of lupus, ongoing medical advancements in the treatment of systemic lupus erythematosus, increasing research and development activities are expected to drive market growth during the forecast period. According to the Lupus Foundation of America, about 1.5 million Americans have a form of lupus, and about 16,000 new cases are reported each year in the Americas. Despite the drivers, the factors such as strict government regulation and increasing prices of lupus drugs may hamper the market growth over the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6636

Currently, a large number of companies are present in the lupus market. The prominent market players are involved in the development of new products and product launches. For instance, in July 2017, GlaxoSmithKline received FDA approval for a new self-injectable formulation of Benlysta for the treatment of adult patients with systemic lupus erythematosus.  

Segmentation

The Global Lupus Market has been segmented into types, treatment, and end user. The global market, on the basis of type, has been segmented into systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. The systemic lupus erythematosus segment is expected to hold the largest market share owing to the growing prevalence and increasing drug development in recent years.

On the basis of treatment, the market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, corticosteroids, immunosuppressants, biologics, and other.

On the basis of end user, the market has been segmented into hospital & clinics, diagnostic laboratories, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The lupus market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European lupus market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The lupus market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The lupus market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, and Eli Lily and Company are some of the key players in the global lupus market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/lupus-market-6636

Desalting and Buffer Exchange Market 2020 Share, Trend, Segmentation And Forecast To 2023

 The Global Desalting and Buffer Exchange Market is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 615.20 million in 2017 and is projected to grow at a CAGR of 10.5% over the forecast period. Desalting is a separation process removes soluble low molecular weight substances from protein and nucleic acid samples. Buffer exchange is the replacement of one set of buffer salts with another set.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6633

Additionally, during the preparation of biological samples, buffer exchange is an essential step, as it prepares the sample for downstream applications. The factors such as growing demand for monoclonal antibodies, increasing research and development expenditure by the biopharmaceutical companies, and growing focus on proteomic and genomic research is expected to drive the market growth over the forecast period.  According to the Office for National Statistics, gross domestic expenditure on R&D was Euro 33.1 billion (USD 35.2 billion) in 2016. Despite the drivers, the lack of skilled professionals is expected to restrain the market growth.

Segmentation

The Global Desalting and Buffer Exchange Market has been segmented into technique, product, and application. On the basis of technique, the market has been segmented into filtration, chromatography, and precipitation. The filtration segment has been further segmented into ultrafiltration and dialysis. The chromatography segment has been segmented into size-exclusion chromatography and others.

The market, by product, has been segmented into kits, cassettes, filter plates, spin columns, membrane filters, and others.

The market, by application, has been segmented into bioprocess applications and diagnostic applications. The bioprocess segment is expected to account for the largest market share in 2017. The market growth of the segment is attributed to the increasing demand for biopharmaceutical products.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The desalting and buffer exchange market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European desalting and buffer exchange market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The desalting and buffer exchange market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The desalting and buffer exchange market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

Merck KGaA, GE Healthcare, Sartorius AG, Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Avantor, Repligen Corporation, Bio-works Technologies Ab, Phynexus, Inc., and Norgen Biotek Corp. are some of the key players in the global desalting and buffer exchange market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/desalting-and-buffer-exchange-market-6633

Bleeding Disorders Treatment Market Size And Key Trends In Terms Of Volume And Value 2023

 The Global Bleeding Disorders Treatment Market is expected to register a growth of significant CAGR 10.0% during the forecast period (2018–2023).

A bleeding disorder is a condition where there is a problem with the body’s clotting method. This disorder leads to heavy and protracted bleeding after an injury. The bleeding process can also start on its own. Most of the types of bleeding disorders are hereditary but some are acquired due to liver diseases, side effects of certain medications, low red blood cell count, vitamin K deficiency and others. The global bleeding disorders treatment market is expected to witness fast growth during the forecast period due to growth in the number of people suffering from liver diseases, anemia, and other blood coagulation disorders.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6592

The global bleeding disorders treatment market is seeing a rise due to growth in the number of diagnosed patients with bleeding disorders, rising research and development activities and investments by key players growth in awareness about bleeding disorders especially hemophilia and positive government initiatives in the developed countries towards establishing a wide network of diagnosis and treatment centers complementing the market growth. However, the absence of access to proper treatment due to the high cost of medication and the shortage of skilled health professionals hinders the growth of the market.

Segmentation

The global bleeding disorders treatment market has been segmented on the basis of type, drug class, treatment and end users.

On the basis of type, the market has been classified as hemophilia A, hemophilia B, Von Willebrand Disease (vWD) and others.

On the basis of drug class, the market has been classified as plasma-derived coagulation factor concentrates market, global recombinant coagulation factor concentrate market, global others bleeding disorders treatment market.

On the basis of treatment, the market has been classified as desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic/clot-stabilizing drugs, fibrin sealants, drugs applied to cuts and pipeline analysis (phase I, phase II and phase III clinical trials)

On the basis of end users, the market has been classified as hospitals, clinics, specialty clinics, research institutes, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European bleeding disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The bleeding disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bleeding disorders treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

In the bleeding disorders treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into drugs. According to the Hemophilia Federation of America, around 20,000 people are affected by hemophilia and approximately 1% of the population is suffering from Von Willebrand Disease (VWD).

The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to Statista, around 149,764 people were diagnosed with hemophilia A and about 10,811 people were diagnosed with other platelet disorders in the year 2016.

Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. According to the annual report survey of 2015 by the World Federation of Hemophilia, it is estimated that there were 17,346 million people suffering from hemophilia.

The market in the Middle East & Africa is expected to account for the smallest share of the global bleeding disorders treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global bleeding disorders treatment market are Shire Plc, Bayer Pharmaceuticals, Novo Nordisk A/S, Pfizer Inc., Biogen Idec, CSL Behring, Grifols, Octapharma, Sun Pharmaceutical Industries Ltd., BDI Pharma, Ferring Pharmaceuticals, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bleeding-disorders-treatment-market-6592

Mastitis Market Segments, Opportunity, Growth And Forecast By End-Use Industry 2023

 The Global Mastitis Market is expected to register a CAGR of 15.07% to reach USD 18,338.80 Million till 2023. Mastitis is an infection in the tissue of one or both mammary glands inside the breast. It usually affects women who are breastfeeding, and it results from a blocked or a plugged duct. In bovine, mastitis is the inflammation of the mammary gland and udder tissue due to bacterial invasion of the teat canal by a variety of bacterial sources present on the farm, and can also occur as a result of chemical, mechanical, or thermal injury to the cow’s udder.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5379

The rising cases of breast cancer, increasing rate of pregnancy, and unhygienic barn conditions causing contagious mastitis in bovines across the globe is expected to enhance the market growth. However, the lack of awareness and complications in diagnosis due to similar symptoms of breast cancer & mastitis are projected to curb the growth of the market.

Market Dynamics

Mastitis has been gaining significance in recent years, owing to the rising incidence of breast cancer. For instance, the Breast Cancer Research Foundation estimated that 266,120 new cases of invasive breast cancer were diagnosed in women in 2018 in the US. Similarly, the UK witnessed around 11,563 deaths due to breast cancer in 2016, according to the Cancer Research UK. Whereas, according to the World Cancer Research Fund International, Belgium had the highest rate of breast cancer in women in 2017. Such a vast population suffering from breast cancer boosts market growth during the forecast period.

Segmentation

The global mastitis market, by type, has been segmented into bovine and human. Based on treatment, the Mastitis market has been categorized as bovine and human. Based on end user, the mastitis market has been classified as veterinary centers and hospital & clinics.

Regional Analysis

The global mastitis market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global mastitis market. North America is expected to dominate the market, mainly due to the increasing p prevalence of mastitis among the bovine population and increasing incidence of breast cancer in the region.

Europe is expected to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are advanced treatment facilities, rising government initiatives to promote healthy breastfeeding, and growing healthcare expenditure. For instance, according to Eurostat, Germany spent over EUR 321 billion in 2014.

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of rapidly developing economies such as China, India, and South Korea. Moreover, the vast patient pool of chronic diseases and government initiatives of healthcare reforms will support the growth of the market.

The mastitis market in the Middle East & Africa is expected to grow due to the affordability and accessibility of healthcare.

Key Players

The prominent players in the global Mastitis market are Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mastitis-market-5379

Egg Allergy Market Growth And Restrain Factors Analysis By 2023

 The Global Egg Allergy Market is expected to register a CAGR of 7.10%and is anticipated to reach USD 2304.3 Million by 2023. Egg allergies are the most common food allergies. Symptoms of egg allergy can occur immediately or within a few minutes or a few hours. Egg allergy can affect infants as well as adults. The adverse effects of egg allergy can vary from hives or rashes to a severe allergic reaction known as anaphylaxis. Egg allergy happens when there is an overreaction to eggs by the immune system. The immune system identifies egg proteins as harmful and triggers an allergic reaction.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4734

The increasing prevalence of egg allergy and improved allergy diagnosis are the major drivers propelling market growth. However, the lack of awareness in developing countries and high cost constrain the growth of the market.

Market Dynamics

The continued growth in several egg allergy patients is responsible for the increasing demand for required diagnostic tests and medication such as epinephrine autoinjectors, and ultimately, it is propelling the growth of the market. For instance, according to the report published by, McGill University in 2016, egg allergy is common in infants and young children and affects 1 to 2% of the preschool children. Additionally, improved allergy diagnosis is likely to support market growth. On the other hand, the lack of awareness in developing countries and high cost is anticipated to hamper the market growth.

Segmentation

The global egg allergy market has been segmented into age type, diagnosis & treatment, and end user. By age type, the market has been segmented into children and adults. The global egg allergy market has two primary sides—diagnosis & treatment. The global egg allergy market, by diagnosis, has been segmented into skin test, blood test, food challenge, and others. The global egg allergy market, by treatment, has been segmented into medication and oral immunotherapy. By end-user, the market has been segmented into hospitals and clinics, diagnostic centers, research institutes, and others. The hospitals and clinics segment accounted for a market value of USD 729.2 million in 2017.  

Key Players

The prominent players in the global egg allergy market are Sanofi SA (France), Genentech, Inc. (the US), Quest Diagnostics (US), ImmuneTech (US), HYCOR Biomedical (US), Kaleo, Inc. (the US), Alletess Medical Laboratory (US), Creative Diagnostics (US), Imutest Ltd (UK), Mylan NV (US), and Impax Laboratories (US).

Some of the key strategies followed by the players operating in the global egg allergy market were innovation, product development, acquisition, and expansion.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/egg-allergy-market-4734

Tissue Microarray Market - Granular Market Report And Review, 2023

 The Global Tissue Microarray Market is expected to register a CAGR of 10.54% and is anticipated to reach USD 10,914.54 million by 2023. Tissue microarrays are paraffin blocks that are created by separating cylindrical tissue cores from different paraffin donor blocks and re-embedding these into a microarray at defined array coordinates. With the help of tissue microarray, up to at least 1000 tissue samples can be arrayed into a single paraffin piece. It allows simultaneous analysis of molecules present in DNA, mRNA, and protein levels under identical, standardized conditions on a single glass slide. This adaptable strategy, in which data analysis is automated, facilitates retrospective and prospective human tissue studies.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1213

The increasing application in drug discovery, increasing prevalence of cancer, growing advancements in biotechnology and pharmaceutical companies, and rising demand for cost-effective and accurate diagnostic methods are the major drivers propelling market growth. However, tissue microarray may not be fruitful for heterogeneous cancers, which is likely to constrain the growth of the market.

Market Dynamics

The prevalence of cancer is one of the crucial factors that drive the growth of the tissue microarray market. According to the American Cancer Society, in 2017, nearly 13% of all cancers diagnosed in adults aged 20. It further stated that rates of liver cancer, thyroid cancer, and melanoma are increasing from last few years. According to US Breast Cancer Statistics, about 1 in 8 US women (about 12%) will develop invasive breast cancer throughout their lifetime. In 2017, an estimated 252,710 new cases of invasive breast cancer were expected to be diagnosed in women in the US, along with 63,410 new cases of non-invasive (in-situ) breast cancer.

Moreover, increasing advancements in biotechnology and pharmaceutical companies and growing demand for cost-effective and accurate diagnostic methods have fueled the growth of the market. On the other hand, tissue microarray is that it may not be fruitful for heterogeneous cancers anticipated to hamper the market growth.

Segmentation

The global tissue microarray market has been divided into the procedure, technology, application, and end user. By procedure, the market has been segregated into immunohistochemistry, fluorescent in-situ hybridization, and frozen tissue array. Based on technology, the market has been segmented into DNA microarray, polymerase chain reaction (PCR), next-generation sequencing, northern blotting, and western blotting. Based on the application, the market has been bifurcated into oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, comparative genomic hybridization, and sequencing bioinformatics. By end-user, the market has been classified as pharmaceutical and biotechnological companies and research organization. The research organization segment accounted for a market value of USD 1876.02 million in 2016.

Key Players

The prominent players in the global tissue microarray market are Agilent Technologies, Illumina, Inc., Protein Biotechnologies Inc., Asterand Bioscience, Pantomics Inc., Applied Microarrays, Arrayit, Phalanx Biotech, QIAGEN, Takara Bio, Perkin Elmer, and Merck Sharp & Dohme Corp.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/tissue-microarray-market-1213